CML
Article
CML: Better response with first-line new-generation TKI therapy vs. imatinib
Article
Ten-year follow-up continue to support nilotinib in Japanese patients with newly diagnosed CML-CP
Article
Need for more precise TKI dosing in real-world CML-CP patients
Article
CML-CP: Elevated creatine kinase levels during first-line TKI treatment associated with improved survival
Article
Risk factors associated with COVID-19 mortality in CML patients
Conference Coverage
Pediatric cancer survivors at risk for opioid misuse
From the Journals
Poor survival with COVID in patients who have had HSCT
Conference Coverage
Omidubicel improves on umbilical cord blood transplants
From the Journals
Don’t delay: Cancer patients need both doses of COVID vaccine
For patients with cancer, immune response to the first dose of the Pfizer COVID-19 vaccine is reduced, and there is a need for a booster dose at...
Conference Coverage
On the horizon: Asciminib, a new drug for treating r/r CML
“Although we have many excellent therapies for CML, having a new medication that targets BCR-ABL in a novel way is still welcome to help us better...
Conference Coverage
Survey quantifies COVID-19’s impact on oncology
Oncologists detail how COVID-19 has impacted care, caregivers, continuing medical education, and clinical trials.